Abbott & Medtronic Pest Positioned Manufacturers in US Neurology Market

As US tariff policies evolve in 2025, neurology device manufacturers face rising cost pressures and growing uncertainty over production strategy. However, Abbott and Medtronic are best positioned among top competitors, with majority of their 510(k)-approved neurology devices manufactured exclusively in the US, respectively, according to the MedSource Database of GlobalData, a leading data and analytics company.

GlobalData’s report, Impact of US Tariffs on the Medical Devices Industry: Strategic Intelligence, reveals that 96% and 57.1% of Abbott and Medtronic’s 510(k)-approved neurology devices manufactured exclusively in the US.

The Market Analyzer on GlobalData’s Medical Intelligence Center reveals that the global neurology device market reached $13.9 billion in 2024, with the US accounting for a dominant $8 billion.

GlobalData estimates that over half of the neurology devices market value is concentrated among five major manufacturers, each with major US operations and a global sales presence. While some companies are shielded from tariffs due to robust domestic manufacturing operations, others may need to reassess their pricing, sourcing, and logistics strategies to stay competitive.

Neurology devices range from emergency-use tools like neurovascular coils and catheters to discretionary products such as neurostimulators for chronic health conditions. While demand for life-saving neurological care remains steady, tariffs are driving up production costs and adding strain to global supply chains. At the same time, hospitals under financial pressure may delay upgrades to diagnostic systems like EEGs or reduce purchases of non-urgent outpatient therapies. As a result, manufacturers face the greatest risk not from declining procedure volumes, but from increased exposure to manufacturing disruptions—especially for products reliant on imports or complex logistics.

Ashley Clarke, Senior Medical Device Analyst at GlobalData, comments: “Even with tighter budgets, hospitals cannot delay urgent neurological procedures like stroke interventions or shunt placements. The real pressure is upstream, with tariffs squeezing margins and compelling companies to rethink where and how their devices are manufactured.”

Abbott and Medtronic continue to expand their domestic capabilities, strengthening their ability to weather tariff impacts and scale efficiently within the world’s most lucrative neurology market. In contrast, Boston Scientific and Stryker face higher exposure, producing just 17.4% and 25.5% of their neurology devices exclusively in the US.

Clarke adds “As tariffs increase cross-border costs and global supply chains become more unpredictable, these companies may need to revise pricing models or restructure logistics to remain cost-effective.”

In this shifting landscape, companies that align research, production, and pricing strategies with the realities of US manufacturing and reimbursement policy are best positioned to protect market share and take the lead in an increasingly complex US neurocare market.

Clarke concludes “Companies with a strong US manufacturing base will be less exposed to price volatility, more consistent on delivery, and in a stronger position when negotiating with hospitals or group purchasing organizations. That is a big advantage in a high-cost, high-stakes field like neurology.”

To gain access to our latest press releases: GlobalData Media Centre

Analysts available for comment. Please contact the GlobalData Press Office:

Email: pr@globaldata.com

Asia-Pacific: +91 40 6616 6809

For expert analysis on developments in your industry, please connect with us on:

GlobalData | LinkedIn | X

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.